Amicus Therapeutics Completes Merger with BioMarin; Shares Converted to Cash at $14.50 and Delisted
Summary
Amicus Therapeutics, Inc. has completed its merger with BioMarin Pharmaceutical Inc.'s subsidiary, becoming a private entity, with shareholders receiving $14.50 cash per share and the stock delisting from Nasdaq.
Key Events
-
Merger Completed
Amicus Therapeutics, Inc. has completed its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., becoming a wholly-owned subsidiary of BioMarin.
-
Cash Consideration for Shareholders
Each outstanding share of Amicus Therapeutics common stock was converted into the right to receive $14.50 in cash, without interest.
-
Delisting from Nasdaq
The company notified Nasdaq of the merger's consummation and its intent to delist and deregister its common stock. Trading was halted on April 27, 2026, and will be suspended on April 28, 2026.
-
Board and Executive Leadership Changes
All previous directors and executive officers of Amicus Therapeutics resigned, and new directors and officers from BioMarin's subsidiary were appointed to the surviving corporation.
Analysis
This 8-K filing formally announces the completion of the previously disclosed merger of Amicus Therapeutics with BioMarin Pharmaceutical Inc.'s subsidiary. For shareholders, this marks the final step in the acquisition, converting their shares into cash at $14.50 per share, a price aligned with the stock's recent trading near its 52-week high. The comprehensive changes detailed, including the complete overhaul of the board and executive management, the termination of a material credit agreement, and the delisting from Nasdaq, signify the company's transition from a public entity to a wholly-owned subsidiary. This event fundamentally alters the investment thesis for Amicus Therapeutics, as it ceases to be an independent publicly traded company.
At the time of this filing, FOLD was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.50. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.